Investors Able to Take Part in Fraud Inquiry Regarding Telix Pharmaceuticals Limited, Led by The Schall Law Firm
The securities investigation into Telix Pharmaceuticals Limited, a Los Angeles-based biopharmaceutical company listed on NASDAQ under the ticker symbol TLX, is ongoing following the disclosure of a subpoena from the U.S. Securities and Exchange Commission (SEC) on July 22, 2025.
The SEC is primarily seeking documents about Telix's disclosures related to the development of its prostate cancer therapeutic candidates. The company, in a statement, has confirmed that this matter is a fact-finding inquiry and is cooperating fully with the SEC. It is important to note that no findings or conclusions have been announced, and Telix stresses that the subpoena does not imply wrongdoing or a violation of securities laws at this stage.
Following the subpoena announcement, Telix's stock price dropped significantly. Several law firms, including Bronstein, Gewirtz & Grossman, LLC and Holzer & Holzer, LLC, are soliciting investors to assist in securities-related investigations and potential class actions. However, as of late July 2025, there is no available information indicating that The Schall Law Firm is conducting such an investigation.
The Schall Law Firm, a national shareholder rights litigation firm, is known for its specialization in securities class action lawsuits and shareholder rights litigation. The firm encourages investors who suffered a loss to participate in the investigation. Investors can contact Brian Schall, Esq., of The Schall Law Firm, to discuss their rights. The Schall Law Firm can be reached via email at [email protected] or by phone at 310-301-3335. The official website for The Schall Law Firm is www.schallfirm.com.
Investors are advised to stay informed about this developing situation. As the investigation progresses, more details may become available. It is essential for investors to seek professional advice if they have any concerns about their investments in Telix Pharmaceuticals Limited.
A cloud of uncertainty hangs over the business sector as the SEC's investigation into Telix Pharmaceuticals Limited's finances continues, with the company's stock price plummeting following the disclosure of a subpoena. In light of this, investors may want to stay informed about news related to the ongoing investigation, as it could potentially impact their investing decisions. The Schall Law Firm, a well-known firm specializing in securities class action lawsuits and shareholder rights litigation, is reportedly soliciting investors to assist in this investigation, though no official announcement has been made yet.
